Innate Pharma S.A. (IPHA)
NASDAQ·Healthcare·Biotechnology
$1.50
+2.74%
Mkt Cap $150.90M
Analyst Ratings
No recent rating data.
Price Target (5 analysts)
$6.67
Range $4.00 – $9.00
Implied Upside
+344.7%
Consensus $6.67 vs current $1.50
NASDAQ·Healthcare·Biotechnology
$1.50
+2.74%
Mkt Cap $150.90M
No recent rating data.
Price Target (5 analysts)
$6.67
Range $4.00 – $9.00
+344.7%
Consensus $6.67 vs current $1.50